The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
[OncoTargets and Therapy] This review discusses the use of targeted therapies to treat pheochromocytoma and paraganglioma, rare tumors that are created from adrenal or extra-adrenal chromaffin cells. Although usually initially benign and nonmetastatic, these tumors can cause serious organ damage and even death.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
